TY - JOUR ID - 133122 TI - Drug repurposing against COVID-19 by GWAS JO - Health Biotechnology and Biopharma (HBB) JA - HBB LA - en SN - Y1 - 2020 PY - 2020 VL - 4 IS - 1 SP - 1 EP - 6 KW - COVID-19 KW - genome-wide association studies KW - drug responsing KW - In Silico DO - 10.22034/HBB.2020.01 N2 - This note is prepared by the authors of a recent publication on shared genetic architecture of drug response based on summary statistics from genome-wide association studies (GWAS) to propose a drug repurposing approach for the treatment of coronavirus COVID-19. The authors proposed that in silico studies may be preceded by analyzing shared genetic architecture of drug response based on existing GWAS. UR - https://www.healthbiotechpharm.org/article_133122.html L1 - https://www.healthbiotechpharm.org/article_133122_9bd27fb0075313cbf2d4d403bcdac5aa.pdf ER -